<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00777348</url>
  </required_header>
  <id_info>
    <org_study_id>H-00982-3256</org_study_id>
    <secondary_id>EudraCT No.: 2007-002553-23</secondary_id>
    <nct_id>NCT00777348</nct_id>
  </id_info>
  <brief_title>To Assess the Protective Effect of the Fixed Drug Combination of Disodium Cromoglycate Plus Reproterol</brief_title>
  <acronym>AERIA</acronym>
  <official_title>Clinical Trial to Assess the Protective Effect of the Fixed Drug Combination of Disodium Cromoglycate Plus Reproterol in Comparison to the Single Components and Placebo in Adults With Exercise Induced Asthma Randomised, Placebo-Controlled, Double-Blind, Crossover, Multicentre Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MEDA Pharma GmbH &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ClinResearch, GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MEDA Pharma GmbH &amp; Co. KG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicentre, randomised, double-blind, placebo-controlled, 4-way cross-over study.&#xD;
      At each study visit a standardised treadmill test will be performed to provoke EIA. Before&#xD;
      and after the challenge test pulmonary function variables (e.g. forced expiratory volume in&#xD;
      one second (FEV1)) will be measured in order to assess the protective effect of the study&#xD;
      medication.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Primary objective: to demonstrate superiority of the protective effect of the fixed&#xD;
           combination of disodium cromoglycate (DSCG) plus reproterol in comparison to the single&#xD;
           component reproterol in adults suffering from exercise induced asthma (EIA).&#xD;
&#xD;
        -  Secondary objectives: to demonstrate superiority of the protective effect of DSCG plus&#xD;
           reproterol in comparison to the single component DSCG; to demonstrate superiority of the&#xD;
           protective effect of each single component in comparison to placebo. In addition, the&#xD;
           tolerability of medications will be documented.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary objective: to demonstrate superiority of the protective effect of the fixed combination of disodium cromoglycate (DSCG) plus reproterol in comparison to the single component reproterol in adults suffering from exercise induced asthma (EIA).</measure>
    <time_frame>5, 10, 15, 30 and 60 minutes after drug application</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary objectives: to demonstrate superiority of the protective effect of DSCG plus reproterol in comparison to the single component DSCG; to demonstrate superiority of the protective effect of each single component in comparison to placebo.</measure>
    <time_frame>5, 10, 15, 30 and 60 minutes after drug application</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Asthma, Exercise-Induced</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DSCG + Reproterol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DSCG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reproterol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination DSCG and Reproterol</intervention_name>
    <description>1:</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female and male subjects aged 18 - 65 years&#xD;
&#xD;
          -  Exercise induced asthma with reversible airway obstruction: twice proven EIA defined&#xD;
             as maximum decrease in FEV1 against the baseline value of at least 20% (first test&#xD;
             results can be obtained during the last 12 months)&#xD;
&#xD;
          -  Baseline FEV1 before challenge must be &gt; or = 70% of the predicted FEV1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Safety concerns:&#xD;
&#xD;
          -  Subjects with hypersensitivity to DSCG, reproterol, menthol, peppermint or other&#xD;
             excipients of the study medication&#xD;
&#xD;
          -  Pregnancy, breast-feeding or planned pregnancy during the study. Women of child&#xD;
             bearing potential not using a highly effective method of birth control defined as&#xD;
             those which result in a low failure rate (i.e. &lt;1% per year) when used consistently&#xD;
             and correctly such as implants, injectables, combined oral contraceptives, hormonal&#xD;
             IUDs, tubal ligation or vasectomised partner&#xD;
&#xD;
          -  Subjects with an asthma exacerbation within 4 weeks prior to the study start. Asthma&#xD;
             exacerbation defined as use of oral (systemic) glucocorticosteroids, unscheduled&#xD;
             consultation of a medic due to asthma, hospitalisation, or additional treatment of&#xD;
             asthma with antibiotics&#xD;
&#xD;
          -  Eosinophilic pneumonia&#xD;
&#xD;
          -  Clinically significant cardiovascular diseases (e.g. cardiac infarction, cardiac&#xD;
             dysrhythmia, hypertrophic obstructive cardiomyopathy, coronary heart disease…)&#xD;
&#xD;
          -  Resting blood pressure over 140/90 mmHg&#xD;
&#xD;
          -  Diastolic blood pressure after treadmill-test over 120 mmHg&#xD;
&#xD;
          -  Malignancies including phaeochromocytoma within the last 5 years&#xD;
&#xD;
          -  Severe hyperthyreosis, thyreotoxicosis, instable diabetes mellitus&#xD;
&#xD;
        Lack of suitability for the trial:&#xD;
&#xD;
          -  Subjects with seasonal asthma during their asthma season&#xD;
&#xD;
          -  Infectious disease of the upper airways within 2 weeks prior to the study and within 4&#xD;
             weeks prior to study in case of use of antibiotics&#xD;
&#xD;
          -  Relevant respiratory disorder other than asthma&#xD;
&#xD;
          -  Clinically significant renal, endocrine, haematological, hepatic, immunological,&#xD;
             gastrointestinal, neurological, or psychiatric diseases&#xD;
&#xD;
          -  Any chronic disease which might influence absorption, metabolism, or excretion of the&#xD;
             trial substances&#xD;
&#xD;
          -  Change of inhalative glucocorticosteroid dosage and / or antiasthmatic controller&#xD;
             therapy within the last 4 weeks prior to or during the study&#xD;
&#xD;
          -  Concomitant systemic treatment with glucocorticosteroids&#xD;
&#xD;
          -  Concomitant treatment with any ß-antagonistic drug&#xD;
&#xD;
          -  Need of rescue medication within 15 min after challenge&#xD;
&#xD;
          -  Concomitant therapy with antidepressants or neuroleptics&#xD;
&#xD;
          -  Drug or alcohol abuse which would interfere with the subjects proper completion of the&#xD;
             protocol assignment and mentally handicapped subjects&#xD;
&#xD;
          -  Smokers within the last 6 months or smoking history &gt; 10 pack-years (a pack-year is 20&#xD;
             cigarettes per day for one year or equivalent)&#xD;
&#xD;
          -  Exposure to another investigational agent within the last 4 weeks prior to this one or&#xD;
             during this study&#xD;
&#xD;
          -  Non-cooperative subjects not able to understand the instructions for use of the&#xD;
             devices&#xD;
&#xD;
        Administrative reasons:&#xD;
&#xD;
          -  Lack of ability or willingness to give informed consent&#xD;
&#xD;
          -  Lack of willingness to have personal study related data collected, archived or&#xD;
             transmitted according to protocol&#xD;
&#xD;
          -  Anticipated non-availability for study visits / procedures&#xD;
&#xD;
          -  Personnel involved in the planning or conduct of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roland Buhl, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research Pneumology, III. Medical Clinic, University Clinic Mainz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kurmittelhaus der Moderne</name>
      <address>
        <city>Bad Reichenhall</city>
        <zip>D-83435</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asthma Center Buchenhoehe</name>
      <address>
        <city>Berchtesgaden</city>
        <zip>D-83471</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice Dr. T. Ginko</name>
      <address>
        <city>Bonn</city>
        <zip>D-53119</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic St. Georg Leipzig, Robert Koch Clinic</name>
      <address>
        <city>Leipzig</city>
        <zip>D-04207</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Pneumology, III. Medical Clinic, University Clinic Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>D-55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice Dr. W. Schürmann</name>
      <address>
        <city>Marburg</city>
        <zip>D-35037</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Pulmonary Research GmbH</name>
      <address>
        <city>Wiesbaden</city>
        <zip>D-65187</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <study_first_submitted>October 21, 2008</study_first_submitted>
  <study_first_submitted_qc>October 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2008</study_first_posted>
  <last_update_submitted>April 7, 2009</last_update_submitted>
  <last_update_submitted_qc>April 7, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2009</last_update_posted>
  <responsible_party>
    <name_title>Meda Pharma GmbH &amp; Co. KG, Dr. DT Nguyen, Senior Medical Manager</name_title>
    <organization>Meda Pharma GmbH &amp; Co. KG, Bad Homburg, Germany</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Asthma, Exercise-Induced</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Reproterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

